纳米粒子在阿尔茨海默氏症疾病中的应用
Yiming Liu1, Yong Shen1,2,3
1Institute on Aging and Brain Disorders, The First Affiliated Hospital of University of Science and Technology of China, Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Journal of Alzheimer's disease : JAD
|October 9, 2023
概括
纳米粒子 (NP) 提供了一个有前途的解决方案,可以通过血脑屏障 (BBB) 传递药物,以治疗神经退行性疾病,如阿尔茨海默病 (AD). 这些微小的材料增强了药物的有效性,并使联合诊断和治疗策略成为可能.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 神经科学是一个神经科学.
背景情况:
- 全球人口老龄化增加了神经退行性疾病的患病率,特别是阿尔茨海默病 (AD).
- 血脑屏障 (BBB) 阻碍了中枢神经系统 (CNS) 疾病的有效药物输送,导致临床试验失败.
- 纳米粒子 (NP) 提供了一种新的方法来克服BBB挑战并改善治疗结果.
研究的目的:
- 审查纳米颗粒 (NP) 在克服血脑屏障 (BBB) 治疗阿尔茨海默病 (AD) 的潜力.
- 探索NP组成,BBB交叉策略和AD病理中的治疗点.
- 为未来基于NP的AD治疗开发提供指导.
主要方法:
- 对纳米粒子在神经退行性疾病的药物输送中的应用进行文献综述.
- 对纳米粒子特征的分析,包括大小,组成和准能力.
- 检查NP用于穿越血脑屏障 (BBB) 的策略.
主要成果:
- 纳米粒子 (NP) 显示出改善生物相容性,延长半衰期和在BBB中增强药物运输的潜力.
- 可以设计NP以针对性地传递到中枢神经系统 (CNS) 中的特定部位.
- 多功能NP为AD等复杂疾病提供综合诊断和治疗能力.
结论:
- 纳米粒子 (NP) 通过解决BBB的局限性,代表了阿尔茨海默病 (AD) 药物输送的重大进步.
- 对NP组成和BBB交叉策略的进一步研究对于优化治疗疗效至关重要.
- 多功能NP的发展有望为个性化和有效的AD治疗和诊断提供希望.
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506


